ND

Active Director Director DIN 10876111
DIN 10876111 First appointment Dec 2024 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Dec 2024
Shareholding value •••• Premium profile

About Nazia Dar

Data last updated:

Nazia Dar is a Director at Protech Biopharma Private Limited (since 2024). The company operates in Pharma. Protech Biopharma Private Limited reported revenue of ₹2.96 Cr (FY 2025).

DIN 10876111
Primary Designation Director
Industry Pharma
First Appointment 14 Dec 2024
Oldest Company Age 19 yrs
Largest company Protech Biopharma Private Limited · ₹2.96 Cr (FY 2025)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Protech Biopharma Private Limited U24233JK2007PTC002841
Director14 Dec 20242007₹2.96 Cr (FY 2025)Active

Board colleagues of Nazia Dar

NameDINCompanyDesignation
Abdul Rehman Mir09434919Protech Biopharma Private LimitedDirector

Directorship timeline

Open interactive timeline →
Protech Biopharma Private Limited
Premium access

Shareholding and investment profile for Nazia Dar

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Nazia Dar

Nazia Dar currently holds 1 directorship: Protech Biopharma Private Limited (Director, since 14 Dec 2024, revenue ₹2.96 Cr (FY 2025)).

Nazia Dar was first appointed on 14 Dec 2024 as Director at Protech Biopharma Private Limited.

The current boards of Nazia Dar's companies include Abdul Rehman Mir (Protech Biopharma Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available